Please use this identifier to cite or link to this item:
|Title:||Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease.||Austin Authors:||Lok, Stacey D;Wong, Alyson W;Khor, Yet H ;Ryerson, Christopher J;Johannson, Kerri A||Affiliation:||Department of Medicine, University of Saskatchewan, Saskatoon, Canada..
Faculty of Medicine, University of Melbourne, Melbourne, Australia..
Central Clinical School, Monash University, Melbourne, Australia..
Respiratory and Sleep Medicine
Department of Medicine, University of British Columbia, Vancouver, Canada..
Departments of Medicine and Community Health Sciences and Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada..
Centre for Heart Lung Innovation, University of British Columbia, Vancouver, Canada..
Institute for Breathing and Sleep
|Issue Date:||Jun-2022||metadata.dc.date:||2021||Publication information:||Chest 2022; 161(6): 1594-1597||URI:||https://ahro.austin.org.au/austinjspui/handle/1/30412||DOI:||10.1016/j.chest.2021.12.636||ORCID:||https://orcid.org/0000-0002-5434-9342||PubMed URL:||34921905||PubMed URL:||https://pubmed.ncbi.nlm.nih.gov/34921905/||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
checked on Jul 2, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.